GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Kedudukan dalam Saham
#3668
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Harga Saham
$27.17
Modal Pasaran
$4.60B
Perubahan (1 hari)
-1.33%
Perubahan (1 tahun)
-13.30%
Negara
IN
Perdagangan GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Nisbah P/E bagi GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Nisbah P/E pada October 2026 TTM: 39.71
Menurut laporan kewangan dan harga saham terkini GlaxoSmithKline Pharmaceuticals Limited, nisbah P/E semasa (TTM) ialah 39.71. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 57.04.
Sejarah nisbah P/E bagi GlaxoSmithKline Pharmaceuticals Limited dari 2004 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 39.71 | -22.28% |
| 2025 | 51.09 | -10.43% |
| 2024 | 57.04 | 55.21% |
| 2023 | 36.75 | 120.55% |
| 2022 | 16.66 | -75.55% |
| 2021 | 68.15 | -70.18% |
| 2020 | 228.54 | 362.35% |
| 2019 | 49.43 | -2.71% |
| 2018 | 50.81 | -26.39% |
| 2017 | 69.02 | -19.51% |
| 2016 | 85.75 | 12.63% |
| 2015 | 76.13 | 44.36% |
| 2013 | 52.74 | 61.36% |
| 2012 | 32.68 | -14.98% |
| 2011 | 38.44 | 8.84% |
| 2010 | 35.32 | 31.37% |
| 2009 | 26.89 | 63.05% |
| 2008 | 16.49 | 3.77% |
| 2007 | 15.89 | -10.92% |
| 2006 | 17.84 | -6.02% |
| 2005 | 18.98 | -4.68% |
| 2004 | 19.91 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 40.53 | 2.07% |
US
|
|
| 38.50 | -3.05% |
US
|
|
| 79.88 | 101.17% |
US
|
|
| 116.96 | 194.55% |
US
|
|
| 22.25 | -43.97% |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.